MXPA03004394A - Profarmacos de cianoguanidina. - Google Patents

Profarmacos de cianoguanidina.

Info

Publication number
MXPA03004394A
MXPA03004394A MXPA03004394A MXPA03004394A MXPA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A
Authority
MX
Mexico
Prior art keywords
optionally substituted
branched
straight
halogen
hydrocarbon radical
Prior art date
Application number
MXPA03004394A
Other languages
English (en)
Inventor
Ernst Torndal Binderup
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MXPA03004394A publication Critical patent/MXPA03004394A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a los compuestos de la formula (I) , en donde X1 y X2 independientemente representan un enlace; un dirradical hidrocarburo lineal, ramificado y/o ciclico, opcionalmente sustituido con uno o mas grupos hidroxilo, halogeno, nitro, amino, ciano, aminosulfonilo, alquilsulfonilamino, alquilcarbonilo, formilo, aminocarbonilo o alquilcarbonilamino; un dirradical hidrocarburo heterociclico heteroarileno o no aromatico, todos los cuales estan opcionalmente sustituidos con uno o mas radicales hidrocarburo lineales, ramificados y/o ciclicos, no aromaticos, los grupos hidroxilo, halogeno, amino, nitro, ciano, aminosulfonilo, alquilsulfonilamino, alquilcarbonilo, formilo, aminocarbonilo o alquilcarbonilamino; Y1 e Y2 representan independientemente un enlace, un dirradical eter ( R' - O - R''), un dirradical amino (R'-N-R''), O, S, S (O), S (O)2, C (O), NH-CO, CO-NH, SO2-N(R'), metileno o N (R') -SO2, en donde R' y R'' representan independientemente dirradicales hidrocarburo lineales o ramificados que contienen hasta 4 atomos de carbono; Y3 representa O, O-C(O), C(O)-O, N (R8), siendo R8 hidrogeno o alquilo de 1 a 4 atomos de carbono; R1 representa hidrogeno o alquilo lineal, ramificado y/o ciclico, opcionalmente sustituido con fenilo; o un radical hidrocarburo aromatico, R2 representa arilo, heteroarilo o un radical hidrocarburo heterociclico no aromatico, todos los cuales estan opcionalmente sustituidos; tetrahidropiraniloxi, di-(alcoxi de 1 a 4 atomos de carbono)fosfinoiloxi o alcoxicarbonilamino de 1 a 4 atomos de carbono; R3 representa hidrogeno; un radical hidrocarburo lineal, ramificado y/o ciclico, opcionalmente sustituido con uno o mas grupos amino, hidroxilo, carboxilo, halogeno, nitro, ciano, alcoxi, aminocarbonilo, alcoxicarbonilo de 1 a 4 atomos de carbono, alcoxicarbonilamino de 1 a 4 atomos de carbono, sulfo, hidroxisulfoniloxi, dihidroxifosfinoiloxi, fosfono, sulfamino, aminosulfonilo, aminoacilamino o dialcoxifosfinoilo; heteroarilo o un radical hidrocarburo heterociclico no aromatico, todos los cuales estan opcionalmente sustituidos con uno o mas radicales hidrocarburo lineales, ramificados y/o ciclicos, los grupos amino, hidroxilo, carboxilo, halogeno, nitro, ciano, alcoxi, aminocarbonilo, alcoxicarbonilo de 1 a 4 atomos de carbono, alcoxicarbonilamino de 1 a 4 atomos de carbono, sulfo, hidroxisulfoniloxi, dihidroxifosfinoiloxi, fosfono, sulfamino, aminosulfonilo, aminoacilarnino o dialcoxifosfinoilo; (a) en donde s es un numero entero de 1 a 200; R6 es hidrogeno o un radical hidrocarburo no aromatico opcionalmente sustituido; R7 es independientemente hidrogeno o metilo; R4 y R5 representan independientemente hidrogeno; un radical hidrocarburo lineal, ramificado y/o ciclico, opcionalmente sustituido con halogeno, hidroxilo, halogeno, amino, nitro o ciano; A representa hidrogeno, un radical hidrocarburo lineal, ramificado y/o ciclico opcionalmente sustituido, hidroxilo, halogeno, nitro, ciano, heteroarilo, heteroaralqu.
MXPA03004394A 2000-11-21 2001-11-14 Profarmacos de cianoguanidina. MXPA03004394A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
PCT/DK2001/000750 WO2002042265A2 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs

Publications (1)

Publication Number Publication Date
MXPA03004394A true MXPA03004394A (es) 2004-04-20

Family

ID=22954502

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004394A MXPA03004394A (es) 2000-11-21 2001-11-14 Profarmacos de cianoguanidina.

Country Status (17)

Country Link
US (1) US6525077B2 (es)
EP (2) EP2894149B1 (es)
JP (1) JP4521157B2 (es)
KR (1) KR100871577B1 (es)
CN (1) CN100368401C (es)
AU (3) AU1494702A (es)
BR (1) BR0115514A (es)
CA (1) CA2426601C (es)
CZ (1) CZ305764B6 (es)
ES (2) ES2549260T3 (es)
HK (2) HK1073297A1 (es)
HU (1) HU230544B1 (es)
IL (2) IL155483A0 (es)
MX (1) MXPA03004394A (es)
PL (1) PL224371B1 (es)
RU (1) RU2312858C2 (es)
WO (2) WO2002042265A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
AU2003229534B2 (en) * 2002-05-17 2009-08-27 Leo Pharma A/S Cyanoguanidine prodrugs
US20060014804A1 (en) * 2002-05-17 2006-01-19 Leo Pharma A/S Cyanoguanidine prodrugs
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
SG160211A1 (en) * 2003-04-03 2010-04-29 Semafore Pharmaceuticals Inc Pi-3 kinase inhibitor prodrugs
WO2006066584A1 (en) 2004-12-22 2006-06-29 Leo Pharma A/S Novel cyanoguanidine compounds
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US8211912B2 (en) * 2007-09-26 2012-07-03 Gemin X Pharmaceuticals Canada Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
EP2342181A1 (en) 2008-08-29 2011-07-13 Topo Target A/S Novel urea and thiourea derivatives
CA2751495C (en) 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
JP2012533530A (ja) 2009-07-17 2012-12-27 トポターゲット・アクティーゼルスカブ ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
KR20140020823A (ko) 2010-09-03 2014-02-19 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 구아니딘 화합물 및 조성물
JP2014514300A (ja) * 2011-04-08 2014-06-19 スファエラ ファーマ ピーティーイー リミテッド 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
JP2015521603A (ja) * 2012-06-15 2015-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 脳癌の新規治療薬
KR20150024932A (ko) * 2012-06-27 2015-03-09 알츠하이머즈 인스티튜트 오브 아메리카, 인크. 화합물 및 그의 치료 용도
US9487500B2 (en) 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
KR102629269B1 (ko) 2015-02-27 2024-01-24 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000093A1 (en) * 1989-06-26 1991-01-10 The Research Foundation Of State University Of New York Bis-acyloxymethyl derivatives
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) * 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds

Also Published As

Publication number Publication date
ES2549260T3 (es) 2015-10-26
PL224371B1 (pl) 2016-12-30
RU2312858C2 (ru) 2007-12-20
CA2426601C (en) 2015-01-13
JP2004520282A (ja) 2004-07-08
CZ305764B6 (cs) 2016-03-09
CN100368401C (zh) 2008-02-13
BR0115514A (pt) 2003-12-30
CN1589262A (zh) 2005-03-02
HUP0400564A2 (hu) 2004-06-28
KR20030051861A (ko) 2003-06-25
WO2002042265A3 (en) 2002-08-15
EP2894149A1 (en) 2015-07-15
EP1339686B1 (en) 2015-09-16
CZ20031303A3 (en) 2004-04-14
EP1339686A2 (en) 2003-09-03
PL362864A1 (en) 2004-11-02
EP2894149B1 (en) 2017-08-02
US6525077B2 (en) 2003-02-25
WO2002042276A1 (en) 2002-05-30
WO2002042265A2 (en) 2002-05-30
US20020165201A1 (en) 2002-11-07
AU1494702A (en) 2002-06-03
HK1073297A1 (en) 2005-09-30
JP4521157B2 (ja) 2010-08-11
AU2002214947B2 (en) 2007-02-15
ES2643083T3 (es) 2017-11-21
HU230544B1 (hu) 2016-11-28
AU2002223511A1 (en) 2002-06-03
KR100871577B1 (ko) 2008-12-02
HK1212678A1 (zh) 2016-06-17
HUP0400564A3 (en) 2008-03-28
IL155483A0 (en) 2003-11-23
CA2426601A1 (en) 2002-05-30
IL155483A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MXPA03004394A (es) Profarmacos de cianoguanidina.
NZ324007A (en) Quinazoline derivatives susbtituted by a phenyl and medicaments
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
ATE345336T1 (de) Benzothiepine als ileal bile acid transport inhibotoren
NO305209B1 (no) N-alkyl-2-substituerte ATP-analoger, slike forbindelser til fremstilling av terapeutikum, farmas°ytisk preparat inneholdende slike forbindelser, og deres anvendelse
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
NO20052802L (no) Pyrrolopyrimidinderivativer
CY1112201T1 (el) Φαρμακο για τη θεραπευτικη αγωγη γριπης
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
MY139446A (en) Novel quinoline derivatives
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EA200100600A3 (ru) Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции
ATE442362T1 (de) Pyridylcyanoguanidin verbindungen
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
HUP0402227A2 (hu) Fenil-szubsztituált triazolok és az AKL5 kináz szelektív inhibitoraiként történő felhasználásuk és a vegyületeket tartalmazó gyógyszerkészítmények
CY1111909T1 (el) Παραγωγα [[2-(αμινο-3,4-διοξο-1-κυκλοβουτεν-1-υλ)amino] αλκυλ]-οξεος για τη θεραπεια του πονου
MXPA03011508A (es) Derivados de imidazol que modulan los canales de sodio.
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
TR200101711T2 (tr) Antihistaminik spiro bileşikler.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
MXPA06001039A (es) Derivados de nicotinamida utiles como inhibidores de pde4.

Legal Events

Date Code Title Description
FG Grant or registration